Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 Monotherapy in ART-Naïve HIV-1
NCT03615183Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-8527 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma HIV-1 RNA at 168 hours, Percentage of Participants Who Report 1 or More Adverse Events (AEs) at 28 days and 1 more. Started Feb 2019; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03615183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615183.